Differences_NNS between_IN United_NNP Kingdom_NNP and_CC United_NNP States_NNPS generally_RB accepted_VBN accounting_NN principles_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD Profit_NN and_CC loss_NN account_NN Adjustments_NNP to_TO the_DT loss_NN for_IN the_DT period_NN under_IN UK_NNP GAAP_NNP and_CC the_DT net_JJ profit_NN under_IN US_NNP GAAP_NNP are_VBP as_IN follows_VBZ :_: Notes_NNP 2003_CD 2002_CD Loss_NN for_IN the_DT period_NN under_IN UK_NNP GAAP_NNP 53.9_CD 45.8_CD US_NNP GAAP_NNP adjustments_NNS :_: Revenue_NN recognition_NN i_FW 27.3_CD 12.7_CD Medeva_NNP goodwill_NN adjustments_NNS ii_VBP 20.1_CD 3.6_CD Amortisation_NNP of_IN goodwill_NN and_CC other_JJ intangibles_NNS iii_FW 64.2_CD 39.8_CD Pension_NN costs_VBZ 0.6_CD 1.9_CD Stock-based_JJ compensation_NN iv_NN 0.9_CD 7.2_CD OGS_NNP acquisition_NN in_IN process_NN research_NN and_CC development_NN v_NN 2.3_CD OGS_NNP acquisition_NN other_JJ vi_FW 3.6_CD Exceptional_JJ items_NNS vii_FW 4.4_CD Unrealised_JJ gains_NNS on_IN derivative_JJ financial_JJ instruments_NNS viii_FW 3.0_CD 6.9_CD Deferred_VBN taxation_NN ix_NN 4.7_CD 5.1_CD Taxation_NNP on_IN GAAP_NNP difference_NN 0.8_CD Net_JJ profit_NN as_IN adjusted_VBN to_TO accord_VB with_IN US_NNP GAAP_NNP 6.0_CD 15.2_CD Shareholders_NNS funds_NNS Adjustments_NNS between_IN shareholders_NNS funds_NNS under_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP are_VBP as_IN follows_VBZ :_: Notes_NNP 2003_CD 2002_CD Shareholders_NNS funds_NNS under_IN UK_NNP GAAP_NNP 505.9_CD 564.4_CD US_NNP GAAP_NNP adjustments_NNS :_: Revenue_NN recognition_NN i_FW 1.5_CD 25.8_CD Goodwill_NNP and_CC intangibles_NNS iii_FW 180.9_CD 163.2_CD OGS_NNP acquisition_NN other_JJ vi_NN 2.2_CD Pensions_NNP 0.4_CD 0.2_CD Pensions_NNS other_JJ comprehensive_JJ income_NN xi_FW 21.0_CD 14.0_CD Unrealised_JJ gains_NNS on_IN derivative_JJ financial_JJ instruments_NNS viii_VBP 5.8_CD 8.8_CD Employee_NNP Share_NNP Ownership_NNP Plan_NNP x_SYM 1.7_CD 0.3_CD Exceptional_JJ items_NNS vii_FW 4.4_CD Deferred_JJ taxation_NN ix_NN 4.7_CD Taxation_NNP 0.8_CD Shareholders_NNS funds_NNS as_IN adjusted_VBN to_TO accord_VB with_IN US_NNP GAAP_NNP 672.1_CD 696.5_CD 82_CD Celltech_NNP Annual_JJ Report_NNP 2003_CD Notes_NNS :_: i_FW Revenue_NN recognition_NN Under_IN UK_NNP GAAP_NNP ,_, non-refundable_JJ licence_NN fee_NN revenue_NN is_VBZ recognized_VBN when_WRB earned_VBN ._.
Refundable_JJ licence_NN fees_NNS are_VBP deferred_VBN until_IN such_JJ time_NN as_IN they_PRP are_VBP no_RB longer_RB refundable_JJ ._.
Arrangements_NNS with_IN multiple_JJ deliverables_NNS are_VBP evaluated_VBN and_CC if_IN the_DT elements_NNS are_VBP determined_VBN to_TO be_VB separable_JJ ,_, these_DT elements_NNS ,_, such_JJ as_IN milestones_NNS and_CC research_NN and_CC development_NN contributions_NNS are_VBP accounted_VBN for_IN separately_RB based_VBN on_IN the_DT revenue_NN recognition_NN criteria_NNS set_VBN out_RP in_IN note_NN 1_CD to_TO the_DT accounts_NNS ._.
US_NNP GAAP_NNP requires_VBZ in_IN most_JJS circumstances_NNS the_DT deferral_NN of_IN non-refundable_JJ upfront_JJ licence_NN fees_NNS and_CC other_JJ income_NN received_VBN under_IN a_DT contract_NN where_WRB there_EX is_VBZ a_DT continuing_VBG involvement_NN with_IN the_DT licensed_JJ asset_NN through_IN collaboration_NN or_CC other_JJ arrangements_NNS ._.
During_IN the_DT year_NN Pfizer_NNP terminated_VBD its_PRP$ relationship_NN on_IN CDP870_CD with_IN Celltech_NNP ._.
Income_NNP previously_RB deferred_VBN under_IN US_NNP GAAP_NNP has_VBZ consequently_RB been_VBN released_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
ii_FW Medeva_FW goodwill_NN adjustments_NNS Under_IN US_NNP GAAP_NNP ,_, the_DT time_NN frame_NN allowed_VBN to_TO make_VB adjustments_NNS to_TO goodwill_NN is_VBZ one_CD year_NN from_IN the_DT date_NN of_IN acquisition_NN ,_, except_IN for_IN adjustments_NNS in_IN respect_NN of_IN taxation_NN when_WRB an_DT indefinite_JJ period_NN is_VBZ available_JJ ._.
Under_IN UK_NNP GAAP_NNP ,_, the_DT time_NN frame_NN available_JJ extends_VBZ to_TO the_DT first_JJ full_JJ reporting_NN period_NN after_IN the_DT reporting_NN period_NN in_IN which_WDT the_DT acquisition_NN was_VBD made_VBN ._.
The_DT 2003_CD adjustment_NN is_VBZ in_IN respect_NN of_IN the_DT settlement_NN of_IN certain_JJ tax_NN exposures_NNS ._.
After_IN the_DT look-back_JJ period_NN ,_, under_IN UK_NNP GAAP_NNP ,_, potential_JJ tax_NN liabilities_NNS that_WDT are_VBP recorded_VBN at_IN acquisition_NN and_CC are_VBP subsequently_RB released_VBN are_VBP recorded_VBN as_IN an_DT income_NN tax_NN benefit_NN ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT release_NN of_IN the_DT tax_NN liability_NN is_VBZ recorded_VBN as_IN an_DT adjustment_NN to_TO goodwill_NN ._.
iii_FW Amortisation_NNP of_IN goodwill_NN and_CC other_JJ intangibles_NNS Under_IN US_NNP GAAP_NNP the_DT merger_NN between_IN Celltech_NNP and_CC Chiroscience_NNP failed_VBD to_TO qualify_VB as_IN a_DT pooling_VBG of_IN interest_NN and_CC therefore_RB additional_JJ goodwill_NN and_CC intangible_JJ assets_NNS were_VBD established_VBN on_IN the_DT US_NNP balance_NN sheet_NN certain_JJ other_JJ differences_NNS also_RB arose_VBD on_IN the_DT acquisitions_NNS of_IN Medeva_NNP and_CC OGS_NNP ._.
In_IN addition_NN ,_, amortisation_NN is_VBZ no_RB longer_RB automatically_RB charged_VBN under_IN SFAS_NNP 142_CD ,_, Goodwill_NNP and_CC Other_JJ Intangible_NNP Assets_NNPS ,_, on_IN goodwill_NN ._.
Amortisation_NNP continues_VBZ to_TO be_VB applied_VBN in_IN the_DT US_NNP on_IN finite_JJ life_NN intangibles_NNS ._.
Goodwill_NN and_CC infinite_NN lived_VBD intangible_JJ assets_NNS are_VBP tested_VBN for_IN impairment_NN annually_RB or_CC when_WRB events_NNS indicate_VBP that_IN assets_NNS may_MD be_VB impaired_VBN ._.
iv_NNP Stock_NNP based_VBN compensation_NN Under_IN UK_NNP GAAP_NNP ,_, no_DT compensation_NN expense_NN is_VBZ recorded_VBN in_IN connection_NN with_IN the_DT issue_NN of_IN share_NN options_NNS to_TO Group_NNP employees_NNS at_IN market_NN value_NN ._.
Under_IN US_NNP GAAP_NNP ,_, APB_NNP 25_CD ,_, an_DT annual_JJ compensation_NN expense_NN is_VBZ imputed_JJ for_IN stock_NN compensation_NN arrangements_NNS based_VBN on_IN the_DT excess_NN of_IN the_DT market_NN price_NN over_IN the_DT exercise_NN price_NN at_IN the_DT measurement_NN date_NN ._.
v_FW OGS_FW acquisition_NN in_IN process_NN research_NN and_CC development_NN Under_IN US_NNP GAAP_NNP ,_, purchase_NN accounting_NN a_DT fair_JJ value_NN exercise_NN is_VBZ performed_VBN to_TO identify_VB in_IN process_NN research_NN and_CC development_NN in_IN an_DT acquired_VBN company_NN ._.
The_DT purchased_VBN in_IN process_NN research_NN and_CC development_NN ,_, once_RB valued_VBN ,_, is_VBZ immediately_RB expensed_VBN ._.
The_DT in_IN process_NN research_NN and_CC development_NN determined_VBN in_IN the_DT preliminary_JJ purchase_NN price_NN allocation_NN has_VBZ been_VBN reduced_VBN to_TO the_DT extent_NN that_IN negative_JJ goodwill_NN was_VBD identified_VBN ._.
vi_FW OGS_FW acquisition_NN other_JJ Under_IN UK_NNP GAAP_NNP ,_, certain_JJ businesses_NNS acquired_VBN with_IN OGS_NNP were_VBD held_VBN for_IN immediate_JJ resale_NN ._.
Provision_NNP for_IN the_DT result_NN of_IN these_DT businesses_NNS notably_RB proteomics_NNS and_CC Confirmant_NNP was_VBD made_VBN in_IN the_DT opening_NN balance_NN sheet_NN ._.
Under_IN US_NNP GAAP_NNP the_DT results_NNS of_IN the_DT businesses_NNS post-acquisition_NN are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
In_IN addition_NN ,_, US_NNP GAAP_NNP and_CC UK_NNP GAAP_NNP differ_VBP in_IN the_DT timing_NN of_IN the_DT recognition_NN of_IN certain_JJ provisions_NNS and_CC closure_NN costs_NNS ._.
vii_FW Exceptional_JJ items_NNS US_NNP GAAP_NNP and_CC UK_NNP GAAP_NNP differ_VBP in_IN the_DT timing_NN of_IN the_DT recognition_NN of_IN certain_JJ redundancy_NN arrangements_NNS and_CC other_JJ closure_NN costs_NNS ._.
viii_FW Unrealised_JJ gains_NNS on_IN derivative_JJ financial_JJ instruments_NNS As_IN described_VBN in_IN note_NN 1_CD to_TO the_DT accounts_NNS Financial_JJ Instruments_NNPS the_DT Group_NNP uses_VBZ forward_RB exchange_NN contracts_NNS to_TO match_VB against_IN forecast_NN receipts_NNS and_CC payments_NNS in_IN foreign_JJ currency_NN ._.
As_IN the_DT contracts_NNS are_VBP not_RB matched_VBN to_TO specific_JJ receivables_NN or_CC payables_NNS the_DT gains_NNS or_CC losses_NNS arising_VBG on_IN the_DT hedges_NNS are_VBP not_RB recognized_VBN until_IN such_JJ time_NN as_IN they_PRP are_VBP realized_VBN under_IN UK_NNP GAAP_NNP ._.
SFAS_NNP 133_CD determines_VBZ that_IN under_IN such_JJ circumstances_NNS recognition_NN should_MD be_VB made_VBN currently_RB of_IN the_DT gains_NNS or_CC losses_NNS that_WDT have_VBP arisen_VBN and_CC should_MD be_VB taken_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
ix_FW Deferred_JJ taxation_NN UK_NNP GAAP_NNP ,_, FRS_NNP 19_CD ,_, requires_VBZ that_IN the_DT Group_NNP recognize_VBP deferred_JJ tax_NN assets_NNS in_IN respect_NN of_IN timing_NN differences_NNS associated_VBN with_IN goodwill_NN ._.
Under_IN US_NNP GAAP_NNP ,_, no_DT deferred_JJ tax_NN liability_NN is_VBZ recognized_VBN on_IN the_DT difference_NN between_IN the_DT financial_JJ carrying_NN value_NN and_CC the_DT tax_NN basis_NN of_IN recorded_VBN goodwill_NN for_IN which_WDT amortisation_NN is_VBZ not_RB deducted_VBN for_IN tax_NN purposes_NNS ._.
x_LS Employee_NNP Share_NNP Ownership_NNP Plan_NNP ESOP_NNP Under_IN UK_NNP GAAP_NNP ,_, the_DT Company_NN 's_POS own_JJ shares_NNS held_VBN by_IN the_DT ESOP_NNP are_VBP recorded_VBN as_IN fixed_JJ asset_NN investments_NNS at_IN cost_NN ._.
Under_IN US_NNP GAAP_NNP those_DT shares_NNS not_RB fully_RB vested_VBN are_VBP regarded_VBN as_IN treasury_NN stock_NN and_CC recorded_VBN at_IN cost_NN as_IN a_DT deduction_NN from_IN shareholders_NNS '_POS equity_NN ._.
xi_FW Pensions_NNS -_: other_JJ comprehensive_JJ income_NN Under_IN US_NNP GAAP_NNP ,_, an_DT additional_JJ minimum_NN pension_NN liability_NN is_VBZ recognized_VBN through_IN other_JJ comprehensive_JJ income_NN in_IN certain_JJ circumstances_NNS when_WRB there_EX is_VBZ a_DT deficit_NN of_IN plan_NN assets_NNS relative_JJ to_TO the_DT accumulated_VBN benefits_NNS obligation_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, SSAP_NNP 24_CD ,_, there_EX is_VBZ no_DT such_JJ requirement_NN ._.
